SCHEMBL10243570

SCHEMBL10243570

CCNCCCN(CC)[C@@H](C)c1ccccc1OC

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 13/20 0.43
ALDH1A1 P00352 2/20 0.39
LMNA P02545 1/20 0.39
GRIN1 Q05586 4/20 0.38
GRIN2A Q12879 4/20 0.38
BCHE P06276 4/20 0.38
ACHE P22303 4/20 0.38
CHRM4 P08173 3/20 0.38
CHRM5 P08912 3/20 0.38
CHRM1 P11229 3/20 0.38
CHRM3 P20309 3/20 0.38
TP53 P04637 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
TSHR P16473 1/20 0.38
THPO P40225 1/20 0.38
RECQL P46063 1/20 0.38
HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10243168 0.96 CHRM2 (0.48) CHRM2GRIN1GRIN2ABCHEACHE
SCHEMBL10243235 0.92 CHRM2 (0.39) CHRM2ALDH1A1BCHEACHE
SCHEMBL10244526 0.88 SLC6A4 (0.40) CHRM2ALDH1A1BCHEACHECYP3A4
SCHEMBL12565837 0.87 CHRM2 (0.39) CHRM2ALDH1A1GRIN1GRIN2ABCHE
SCHEMBL10245606 0.84 CHRM2 (0.43) CHRM2ALDH1A1GRIN1GRIN2ABCHE
SCHEMBL12565838 0.83 CHRM2 (0.43) CHRM2ALDH1A1GRIN1GRIN2ABCHE
SCHEMBL10244221 0.83 ALDH1A1 (0.38) CHRM2ALDH1A1LMNAACHETSHR
SCHEMBL12608561 0.82 ALDH1A1 (0.39) ALDH1A1LMNA
SCHEMBL10243135 0.82 APP (0.43) BCHEACHE
SCHEMBL10282710 0.82 APP (0.43) LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8299035-B2 10a-azalide compound having 4-membered ring structure TAISHO PHARMACEUTUCAL CO., LTD. (JP) 2012-10-30 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20110152239-A1 10A-AZALIDE COMPOUND HAVING 4-MEMBERED RING STRUCTURE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2011-06-23 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110152239-A1 10A-AZALIDE COMPOUND HAVING 4-MEMBERED RING STRUCTURE ELOVL3, ELOVL5, SCD5 CHRM2 3997/4885ALDH1A1 3050/4885LMNA 1555/4885
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 CHRM2 3989/4885ALDH1A1 1939/4885LMNA 1467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.